Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Ast...( Scientific Presentations Take Center ...),Health

Scientific Presentations Take Center Stage at Educational Symposium as Xoft Launches New Oncology Products and Axxent(R) Xpress(TM) Transportable eBx

Vehicles

BOSTON, Sept. 22 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy (eBx) System, which delivers non-radioactive, electronic therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue, will showcase early clinical experience with its growing suite of oncology treatment technologies here at the 49th American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting, September 21-24. Developed for the treatment of early stage breast cancer, the Axxent System also has applicators for endometrial and rectal indications and is FDA cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. To date, more than 35 Axxent Systems have been shipped nationwide.

Initial data from the phase IV study, "Early experience with an electronic brachytherapy technique for intracavitary accelerated partial breast irradiation (APBI)," will be presented at an Industry Satellite Symposium hosted by Xoft in conjunction with the ASTRO. The presentation will be made by Vivek Mehta, MD, director, Center for Advanced Targeted Radiotherapies at Swedish Cancer Center in Seattle and Radiation Oncology Principal Investigator for the study.

According to Dr. Mehta, clinical experience with the Axxent System for many study patients followed to six months and beyond demonstrates that the X-Ray-based, non-isotopic treatment is a viable option for adjuvant therapy for early-stage breast cancer. After the tumor had been removed with lumpectomy surgery, the Axxent System was used to deliver radiation therapy directly to the tumor bed over five days instead of the standard five to seven week course of treatment. "While we will be monitoring these patients for the next five years, th
'/>"/>